At a Glance
| Generic name | Cytarabine |
| Brand names | Cytosar-U (conventional); Vyxeos (liposomal + daunorubicin); DepoCyt (liposomal intrathecal) |
| Drug class | Antimetabolite → Cytidine analog |
| Cell-cycle specificity | CCS — S-phase |
| Route | IV (infusion or bolus), SC, Intrathecal |
| FDA approval | 1969 (conventional); 2017 (Vyxeos); 1999 (DepoCyt) |
Mechanism of Action
Cytarabine (1-β-D-arabinofuranosylcytosine, ara-C) is structurally identical to cytidine except for the arabinose sugar in place of ribose, which positions the 2′-hydroxyl group in the trans configuration — sterically blocking normal DNA polymerase function after incorporation.
Step-by-step intracellular activation:
Cytarabine (ara-C)
↓ deoxycytidine kinase (dCK) ← rate-limiting step
ara-CMP (monophosphate)
↓ UMP-CMP kinase
ara-CDP (diphosphate)
↓ nucleoside diphosphate kinase
ara-CTP (triphosphate) ← active cytotoxic form
ara-CTP exerts cytotoxicity by:
- Competitive inhibition of DNA polymerase-α and -β — competes with endogenous dCTP for incorporation into elongating DNA strands
- Chain termination — once incorporated, the arabinose configuration causes polymerase stalling; additional nucleotides cannot be added efficiently
- Inhibition of DNA repair — ara-CTP inhibits DNA polymerase-β, which is responsible for base excision repair, preventing cells from correcting drug-induced damage
The ara-CTP:dCTP ratio is the key pharmacodynamic determinant. Cytotoxicity correlates not with plasma ara-C levels but with intracellular ara-CTP accumulation relative to the competing dCTP pool. This ratio drives:
- The rationale for high-dose regimens (saturating the phosphorylation pathway to maximize ara-CTP)
- The resistance mechanism (upregulation of dCTP pool via RNR — the same target gemcitabine addresses)
- Schedule dependency (prolonged infusions expose more S-phase cells than bolus dosing)
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability (oral) | <20% — not used orally; rapid first-pass deamination by CDA in gut/liver |
| Bioavailability (SC) | ~100% — used for low-dose/maintenance subcutaneous regimens |
| Distribution | Widely distributed; crosses blood-brain barrier (CSF levels ~40% of plasma at standard doses) |
| Protein binding | ~13% — low, not clinically relevant |
| Metabolism | Deaminated by cytidine deaminase (CDA) → ara-U (uracil arabinoside, inactive); occurs in plasma, liver, kidney, GI tract |
| Elimination half-life | Biphasic: α ~10 min, β ~1–3 hours |
| Renal excretion | ~80% excreted as ara-U in urine |
Key PK-PD relationship — why dose level matters:
At standard doses (100–200 mg/m²), dCK is not saturated and ara-CTP accumulation is proportional to dose. At high doses (≥2–3 g/m²), dCK becomes saturated — further dose escalation adds toxicity without proportionally increasing ara-CTP. This is why HiDAC has a functional ceiling and why schedule (prolonged infusion vs. bolus) can meaningfully alter efficacy at standard doses.
Formulations and Dose Levels
Cytarabine is unique in having three clinically distinct dose tiers — each with a different indication, toxicity profile, and monitoring requirement. Treating them interchangeably is a serious error.
1. Standard-Dose Cytarabine (SD ara-C)
- Dose: 100–200 mg/m²/day continuous IV infusion × 7 days (classically in 7+3 AML induction)
- Indication: AML induction (with anthracycline), consolidation in lower-risk settings, ALL
- Key toxicities: Myelosuppression, mucositis, nausea/vomiting, mild hepatotoxicity
- Monitoring: CBC, LFTs, renal function
2. Intermediate-Dose Cytarabine (ID ara-C)
- Dose: 500–1,500 mg/m² (typically 1,000 mg/m² q12h × 6 doses)
- Indication: AML consolidation (intermediate risk), relapsed/refractory ALL, lymphoma salvage regimens (e.g., ESHAP, DHAP)
- Key toxicities: Myelosuppression ++, conjunctivitis (steroid eye drops required), beginning of cerebellar risk
- Monitoring: CBC, neurologic assessment, ophthalmologic symptoms
3. High-Dose Cytarabine (HiDAC)
- Dose: ≥2–3 g/m² q12h × 6 doses (total 12 g/m² per cycle)
- Indication: AML consolidation in fit patients (especially favorable/intermediate cytogenetics — inv(16), t(8;21), NPM1-mutated), conditioning regimens, relapsed/refractory AML
- Key toxicities:
- Cerebellar toxicity (most feared) — ataxia, dysarthria, nystagmus; irreversible if not caught early; risk factors: age >60, renal impairment (creatinine >1.5 or CrCl <60), prior CNS disease
- Conjunctivitis — chemical; requires steroid eye drops (prednisolone 1% q6h) prophylactically during therapy and 24–48h after
- Severe myelosuppression, skin rash (palmar-plantar), alopecia, hepatotoxicity
Pharmacist-critical: Before each HiDAC dose, a standardized neurologic assessment (Romberg test, finger-nose test, gait, nystagmus check) must be performed by nursing/physician. If cerebellar signs develop, cytarabine must be held immediately — progression to irreversible ataxia can occur with continued dosing.
Vyxeos (Liposomal Cytarabine + Daunorubicin)
What It Is
Vyxeos is not cytarabine plus daunorubicin given together — it is a fixed 5:1 molar ratio of cytarabine:daunorubicin co-encapsulated within the same liposome. This distinction matters profoundly.
Why the 5:1 ratio? Extensive preclinical work by the developers demonstrated that synergy between cytarabine and daunorubicin against AML blasts was ratio-dependent, not simply additive. The 5:1 molar ratio produced maximal synergistic cytotoxicity in AML cell lines and primary blast samples; other ratios were less effective or even antagonistic. The liposomal co-encapsulation maintains this ratio from administration through to intracellular delivery — ensuring both drugs arrive at the target simultaneously and at the synergistic ratio.
Indication
FDA-approved for:
- Therapy-related AML (t-AML)
- AML with myelodysplasia-related changes (AML-MRC)
These are the two highest-risk AML subtypes — historically poor responders to conventional 7+3. The pivotal trial (CPX-351 / JAZZ trial) showed significantly improved OS vs. conventional 7+3 in older adults (60–75 years) with these subtypes.
Dosing
| Phase | Dose | Days |
|---|---|---|
| Induction (1st) | Cytarabine 100 mg/m² + Daunorubicin 44 mg/m² (as Vyxeos) | Days 1, 3, 5 |
| Induction (2nd, if needed) | Same | Days 1, 3 |
| Consolidation | Same | Days 1, 3 |
Dosing is always expressed as the cytarabine component. Do not confuse with standard 7+3 dosing.
Key Differences from 7+3
| Conventional 7+3 | Vyxeos | |
|---|---|---|
| Schedule | Ara-C CI × 7d + Dauno × 3d | Days 1, 3, 5 bolus |
| Myelosuppression duration | Shorter | Prolonged — expect longer time to count recovery |
| Cardiac monitoring | Standard | Enhanced — liposomal anthracycline; standard LVEF monitoring |
| Infusion time | Short | 90-minute infusion |
| Extravasation risk | Vesicant (daunorubicin) | Vesicant — central line preferred |
| Interchangeability with 7+3 | N/A | Not interchangeable — different indication, schedule, and formulation |
Intrathecal Cytarabine
Conventional IT Cytarabine
- Used for CNS prophylaxis and treatment in ALL, some AML protocols, and lymphoma with CNS involvement
- Dose: Typically 30–70 mg IT (age-based and protocol-specific); some protocols use weight-based dosing in pediatrics
- CRITICAL dispensing rule: Must use preservative-free formulation only — benzyl alcohol (present in some multi-dose vials) is neurotoxic and has caused deaths when administered intrathecally
DepoCyt (Liposomal IT Cytarabine)
- Indicated specifically for lymphomatous meningitis
- Dose: 50 mg IT q14 days (induction and consolidation phases)
- Mandatory co-administration: Dexamethasone 4 mg PO or IV BID × 5 days starting the day of each DepoCyt injection — without this, chemical arachnoiditis (severe headache, fever, neck stiffness, nausea) is common and can be severe
- Prolonged CSF cytarabine levels (active drug detectable for up to 14 days) is the pharmacologic advantage over conventional IT cytarabine (cleared within hours)
Toxicity Profile
| Toxicity | Dose-Level Association | Notes |
|---|---|---|
| Myelosuppression | All doses | Nadir typically day 7–14; dose-dependent depth and duration |
| Mucositis / stomatitis | SD, ID | Oral hygiene protocol; dose-limiting at SD with CI |
| Nausea / vomiting | All | Moderate emetogenicity; 5-HT₃ antagonist ± dexamethasone |
| Cerebellar neurotoxicity | HiDAC | Age >60, renal impairment major risk factors; IRREVERSIBLE if missed |
| Conjunctivitis | ID, HiDAC | Chemical; steroid eye drops prophylaxis mandatory |
| Palmar-plantar erythema | HiDAC | Dose-limiting in some patients |
| Hepatotoxicity | HiDAC | Transaminase elevation; cholestatic pattern; usually reversible |
| Ara-C syndrome | Any | Fever, malaise, myalgia, rash 6–12h post-dose; responds to corticosteroids |
| Tumor lysis syndrome | Induction doses | High-risk; uric acid–lowering prophylaxis mandatory |
| Alopecia | All | Universal at induction doses |
| Chemical arachnoiditis | IT (DepoCyt) | Prevented by mandatory dexamethasone co-administration |
Ara-C Syndrome — Worth Knowing
A distinct hypersensitivity-like syndrome occurring 6–12 hours after cytarabine administration: fever, myalgia/bone pain, rash, conjunctivitis, chest pain, malaise. Not an allergic reaction in the classical sense — likely cytokine-mediated. Treated with corticosteroids (and steroids can be continued prophylactically in subsequent cycles). Does not require drug discontinuation unless severe.
| Interaction | Mechanism | Clinical Implication |
|---|---|---|
| Flucytosine (5-FC) | Cytarabine inhibits conversion of 5-FC → 5-FU intracellularly | Reduces antifungal efficacy of 5-FC; avoid concurrent use |
| Digoxin (oral tablets) | Cytarabine-induced GI mucosal damage reduces digoxin absorption | Monitor digoxin levels; switch to liquid or IV if needed |
| Live vaccines | Immunosuppression | Contraindicated during and for period after therapy |
| Methotrexate (IT) | Sequence-dependent synergy | Give MTX before ara-C IT for maximal CNS effect (protocol-specific) |
| G-CSF timing | G-CSF given concurrently may expand myeloid progenitors susceptible to ara-C | Typically held during chemotherapy; protocol-specific |
Dose Modifications
Renal Impairment
| CrCl | Conventional | HiDAC |
|---|---|---|
| >60 mL/min | Full dose | Full dose |
| 30–60 mL/min | Full dose (monitor) | Reduce to 1 g/m² — significantly increases cerebellar toxicity risk |
| <30 mL/min | Reduce / individualize | Avoid or reduce substantially |
Hepatic Impairment
- No formal dose modification guidelines for conventional doses
- HiDAC: use caution with significant hepatic dysfunction (bilirubin >2× ULN); ara-C is not primarily hepatically eliminated but hepatotoxicity is additive
Cerebellar Toxicity — Hold/Discontinue Criteria
- Any grade cerebellar signs (ataxia, nystagmus, dysarthria, dysdiadochokinesia): hold dose immediately
- Do not rechallenge with HiDAC if cerebellar toxicity occurs — risk of permanent irreversible damage
Key Clinical Trials
| Trial | Regimen | Key Finding |
|---|---|---|
| AMLSG 07-04 | HiDAC consolidation in CN-AML | Established HiDAC superiority over SD ara-C in consolidation for favorable/intermediate cytogenetics |
| CALGB 8525 | HiDAC vs. ID vs. SD consolidation | HiDAC (3 g/m²) superior DFS in AML CR1 — landmark trial establishing HiDAC as standard |
| CPX-351 (JAZZ) | Vyxeos vs. 7+3 in t-AML/AML-MRC, age 60–75 | Significant OS benefit (9.56 vs. 5.95 months median); higher CR rate; better bridge to transplant |
Pharmacist Watchouts
- Formulation non-interchangeability: Conventional IV ≠ Vyxeos ≠ DepoCyt ≠ IT cytarabine. Verify indication, route, and formulation on every order.
- Preservative-free mandate for IT use — verify vial formulation before dispensing any intrathecal cytarabine.
- HiDAC cerebellar monitoring — confirm nursing neurologic assessment protocol is in place before each dose. Communicate directly with the team if assessment is not documented.
- Steroid eye drops with ID/HiDAC — prednisolone 1% ophth (or equivalent) must be ordered prophylactically. A common omission.
- DepoCyt + dexamethasone — dexamethasone is not optional; verify it is prescribed with every DepoCyt dose.
- Renal dose adjustment for HiDAC — check CrCl before each cycle; reduce to 1 g/m² if CrCl <60. Escalating creatinine mid-cycle warrants urgent dose-hold discussion with the team.
- TLS prophylaxis — allopurinol or rasburicase per institutional TLS risk protocol; high risk in induction.
- Emetogenicity — moderate; 5-HT₃ antagonist required; dexamethasone sometimes omitted in AML patients already on steroids — verify antiemetic coverage is adequate.
- Vyxeos infusion time — 90-minute infusion; not to be confused with conventional ara-C infusion schedules.
- 5-FC interaction — flag any patient on fluconazole-refractory fungal coverage with 5-FC; cytarabine antagonizes it.